2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations.
Publication/Presentation Date
12-10-2019
Abstract
The American Society of Hematology (ASH) convened 5 guideline panels to develop clinical practice recommendations addressing 5 management areas of highest importance to individuals living with sickle cell disease: pain, cerebrovascular complications, pulmonary and kidney complications, transfusion, and hematopoietic stem cell transplant. Panels were multidisciplinary and consisted of patient representatives, content experts, and methodologists. The Mayo Clinic Evidence-Based Practice Center conducted systematic reviews based on a priori selected questions. In this exposition, we describe the process used by ASH, including the GRADE approach (Grades of Recommendations, Assessment, Development and Evaluation) for rating certainty of the evidence and the GRADE Evidence to Decision Framework. We also describe several unique challenges faced by the guideline panels and the specific innovations and solutions used to address them, including a curriculum to train patients to engage in guideline development, dealing with the opioid crisis, and working with indirect and noncomparative evidence.
Volume
3
Issue
23
First Page
3945
Last Page
3950
ISSN
2473-9537
Published In/Presented At
Murad, M. H., Liem, R. I., Lang, E. S., Akl, E. A., Meerpohl, J. J., DeBaun, M. R., Tisdale, J. F., Brandow, A. M., Lanzkron, S. M., Chou, S. T., Webb, S., & Mustafa, R. A. (2019). 2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood advances, 3(23), 3945–3950. https://doi.org/10.1182/bloodadvances.2019000931
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31794603
Department(s)
Administration and Leadership
Document Type
Article